Switch from ABCD pretreatment to A-II-A treatment: A multinational, open, centrally randomized, prospective parallel group comparison

Drugs under Experimental and Clinical Research

Volumn 30, Issue 4, 2004, Pages 153-161

  Asmar, Roland ^a,d   Porcellati, C ^b   Dusing, R ^c  

^a Cardiovascular Institute   (France)

^b Silvestrini Hospital   (Italy)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d L'Institut CardioVasculaire   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALDACTAZINE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; BLOOD PRESSURE; DATA INTERPRETATION, STATISTICAL; DEMOGRAPHY; FEMALE; HEART RATE; HUMANS; HYPERTENSION; INTERNATIONAL COOPERATION; MALE; METHODS; MIDDLE AGED; PATIENT SELECTION; POSTURE; PROSPECTIVE STUDIES; TETRAZOLES; THERAPEUTIC HUMAN EXPERIMENTATION; TIME FACTORS; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 8444244019     PISSN: 03786501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Staessen J.A., Wang J., Bianchi G., Birkenhager W.H. Essential hypertension. Lancet, 361(9369), 1629, 2003.
2. Lindholm L.H. The problem of uncontrolled hypertension. J. Hum. Hypertens., 16(Suppl 3), S3, 2002.
3. Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA, 289(19), 2560, 2003.
4. Andersson O.K. Tolerability of a modern antihypertensive agent: candesartan cilexetil. Basic Res. Cardiol., 93(Suppl. 2), 54, 1998.
5. Lacourciere Y., Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: A placebo-controlled, forced titration study. Candesartan/Losartan study investigators. Am. J. Hypertens., 12(12 Pt 1-2), 1181, 1999.
6. Asmar R., Lacourciere Y. A new approach to assessing antihypertensive therapy: Effect of treatment on pulse pressure. Candesartan cilexetil in Hypertension Ambulatory Measurement of Blood Pressure (CHAMP) Study Investigators. J. Hypertens., 18(11), 1683, 2000.
7. Burt V.L., Cutler J.A., Higgins M., et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension, 26(1), 60, 1995.
8. Mancia G., Sega R., Milesi C., Cesana G., Zanchetti A. Blood-pressure control in the hypertensive population. Lancet, 349(9050), 454, 1997.
9. McClellan K.J., Goa K.L. Candesartan cilexetil. A review of its use in essential hypertension. Drugs, 56(5), 847, 1998.
10. Sever P.S. Key features of candesartan cilexetil and a comparison with other angiotensin II receptor antagonists. J. Hum. Hypertens., 13(Suppl. T), S3, 1999.
11. Elmfeldt D., George M., Hubner R., Olofsson B. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect. J. Hum. Hypertens., 11(Suppl. 2), S49, 1997.
12. Lewis M.J., Ross P.J., Henderson A.H. Rebound effect after stopping beta-blockers. Br. Med. J., 2(6190), 606, 1979.
13. Haralambos P., Gavras P. Issues in hypertension: Drug tolerabilityand special populations. Am. J. Hypertens., 14(Suppl. 7 Pt 2), 231S, 2001.
14. Dusing R. Adverse events, compliance, and changes in therapy. Curr. Hypertens. Rep., 3(6), 488, 2001.
15. Sever R, Holzgreve H. Long-term efficacy and tolerability of candesartan cilexetil in patients with mild to moderate hypertension. J. Hum. Hypertens., 11(Suppl. 2), S69, 1997.
16. Belcher G., Hubner R., George M., Elmfeldt D., Lunde H. Candesartan cilexetil: Safety and tolerability in healthy volunteers and patients with hypertension. J. Hum. Hypertens., 11(Suppl. 2), S85, 1997.
17. McInnes G.T., O'Kane K.P., Jonker J., Roth J. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population. J. Hum. Hypertens., 11(Suppl. 2), S75, 1997.
18. Gabbay E., Small T., Corris P.A. Angiotensin converting enzyme inhibitor cough: Lessons from heart-lung transplantation. Respirology, 3(1), 39, 1998.
19. Sadick N.S., Katz A.S., Schreiber T.L. Angioedema from calcium channel blockers. J. Am. Acad. Dermatol., 21(1), 132, 1989.
20. Kloner R.A., Weinberger M., Pool J.L., et al. Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators. Am. J. Cardiol., 87(6), 727, 2001.
21. Zanchetti A., Omboni S., Di Biagio C. Candesartan cilexetil and enalapril are of equivalent efficacy in patients with mild to moderate hypertension. J. Hum. Hypertens., 11(Suppl. 2), S57, 1997.